Lung cancer risk particularly high for heart and liver transplant recipients

May 1, 2010, European Society for Medical Oncology

Heart and liver transplant recipients are at particularly high risk of developing lung cancer after receiving the donated organ, researchers report at the 2nd European Lung Cancer Conference. They are advising doctors to screen for such cancers in these patients to maximize the chance of detecting the malignancy early.

Doctors have known for decades that the immunosuppressive drugs given to transplant patients increase their risk of developing new cancers. In transplant patients, the risk of developing a ranges from 4% to 18% and may be 100-fold higher than in the general population. The most common malignancies after transplantation are cancers of the lips and skin, lymphoproliferative disorders and Kaposi's .

In a new study, French researchers studied the risk of developing in patients who received different types of solid organs. Theirs is the largest study to date exploring the development of lung cancer in transplant recipients.

The researchers followed a group of 2,831 patients who received organ transplants at Toulouse Hospital between February 1984 and September 2006. Overall, 0.85% of them developed a lung cancer after transplant.

"We observed that 10 lung cancers occurred after (0.5%), 8 after (1.3%) and 6 after heart transplantation (2.8%). This difference is statistically significant," said Dr Julien Mazieres, the study coordinator.

"The high incidence of lung cancer in heart transplant and liver transplant recipients may be because more of these patients have a heavy smoking history compared to kidney transplant recipients," he said. The average number of packs per year was 75.2 for heart-transplant patients, 40 for liver-transplant recipients and 28.5 for kidney-transplant recipients.

The researchers say that transplant patients should be screened for expected cancers for which early detection and treatment is associated with a better prognosis. This is particularly true for skin cancers.

Doctors should also consider screening for lung cancer, they say. "We can reasonably think that a close follow-up including chest examination and X-ray is easy to do and useful," Dr Mazieres said. "At least, physicians taking care of transplant recipients should have in mind the increased risk of cancer and integrate this risk factor in their follow-up to improve the survival of these patients."

Related Stories

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.